Can-Fite BioPharma Ltd. Share Price Nyse

Equities

CANF

US13471N1028

Pharmaceuticals

End-of-day quote Nyse 04:30:00 05/02/2024 am IST 5-day change 1st Jan Change
2.02 USD -3.35% Intraday chart for Can-Fite BioPharma Ltd. -4.04% -8.18%
Sales 2024 * 9L 7.52Cr Sales 2025 * 9L 7.52Cr Capitalization 1.19Cr 100Cr
Net income 2024 * -70L -58Cr Net income 2025 * -80L -67Cr EV / Sales 2024 * 13.3 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 13.3 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.97%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Can-Fite BioPharma Ltd. - Special Call
Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study CI
Transcript : Can-Fite BioPharma Ltd. - Special Call
Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 CI
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study CI
Can-Fite Biopharma Ltd. Announces Clinical Update CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office CI
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication CI
Can-Fite Biopharma Ltd. Announces Results from Randomized Phase 3 Clinical Trial CI
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson?s Anti-Obesity Mechanism of Action CI
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan RE
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson CI
More news

Latest transcript on Can-Fite BioPharma Ltd.

Managers TitleAgeSince
Chief Executive Officer 59 01/03/01
Founder 74 11/94/11
Founder 68 11/94/11
Members of the board TitleAgeSince
Director/Board Member 76 01/01/01
Founder 68 11/94/11
Founder 74 11/94/11
More insiders
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.03
Average target price
-
Consensus